- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03792503
Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen
Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical Study
Study Overview
Status
Intervention / Treatment
Detailed Description
In patients with advanced non-squamous non-small cell lung cancer, patients receiving pemetrexed and platinum-based chemotherapy after 4 cycles of non-progressive evaluation were treated with pemetrexed plus apatinib. Until the disease progresses, there are intolerable side effects or the patient requests to withdraw from the study. It is planned to include 20 subjects.
Dosing regimen: Apatinib 500mg po qd (If there is a 3-4 degree toxic side reaction after 14 days of administration, the dose can be lowered to 250mg qd); Pemetrexed 500 mg/m2 d1×q3w; Until the patient progresses, the toxicity is intolerable, the patient withdraws his knowledge, or the investigator judges that the medication must be discontinued.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Chongqing, China, 400000
- Xinqiao Hospital of Chongqing
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Stage IV non-squamous non-small cell lung cancer diagnosed by pathology.
- At least one measurable lesion.
- If the genetic test (EGFR/ALK) is an EGFR-sensitive mutation or an ALK fusion gene-positive patient, it is necessary to receive targeted therapy for the first-line treatment; if there is no mutation, it is necessary to be a first-line patient.
- Pemetrexed combined platinum induction chemotherapy after 4 cycles of RECIST curative effect evaluation of patients who were not progress.
- Gender is not limited, age: ≥ 18 years old.
- ECOG PS: 0-2 points.
- Estimated lifetime ≥3 months
Organ function levels meet the following criteria:
- Blood routine examination standards must meet: ANC≥1.5×109/L, PLT≥100×109/L, Hb≥100g/L (No blood transfusion and blood products within 14 days, not corrected by G-CSF and other hematopoietic stimulating factors).
- Biochemical examination must be in accordance with the following criteria: TBIL<1.5×ULN, ALT, AST and ALP<2.5×ULN, BUN and Cr≤1×ULN or Endogenous creatinine clearance≥50ml/min (Cockcroft-Gault formula).
- Women of childbearing age must have reliable contraceptive measures, or in the group of 7 days before the pregnancy test (serum or urine), and the results were negative, and willing to during the test and the last for 8 weeks after experimental drug using appropriate methods of contraception.For men, must be agreed to at the end of the experiments and tests of giving drugs after 8 weeks using appropriate methods of contraception or has sterilization surgery.
- Subjects were willing to join in this study, signed informed consent, good adherence, cooperate with the follow-up.
Exclusion Criteria:
- Squamous cell carcinoma (including adenosquamous carcinoma), small cell lung cancer (including small cell carcinoma and non-small cell mixed lung cancer).
- Patient gene detection is EGFR sensitive mutation, or positive for ALK fusion gene.
- Symptomatic brain metastasis (a patient with brain metastases who completed treatment and had stable symptoms 21 days before enrollment can be enrolled, but need to be confirmed by brain MRI, CT or venography to have no cerebral hemorrhage symptoms).
- Imaging (CT or MRI) showed tumor lesions ranging from ≤ 5 mm to large vessels, or central tumors that invaded local large blood vessels; or showed significant pulmonary cavitary or necrotizing tumors.
- Hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) that is still uncontrollable using a combination of two antihypertensive drugs.
- Have the following cardiovascular diseases: myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmias (including men with QTc interval ≥ 450 ms, women ≥ 470 ms); according to NYHA criteria, grade III to IV cardiac insufficiency, Or cardiac color Doppler ultrasound examination indicates left ventricular ejection fraction (LVEF) <50%.
- Patients with a history of pulmonary interstitial disease or a patient with pulmonary interstitial disease.
- Abnormal coagulation (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds or APTT > 1.5 ULN), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy.
- There is obvious cough blood in the 2 months before enrollment, or the daily hemoptysis amount is 2.5ml or more.
- Into the group of the first 3 months there have been significant clinical significance of bleeding symptoms or have definite bleeding tendency.
- Events of arterial/venous thrombosis occurring within 12 months prior to enrollment, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism,etc.
- Known hereditary or acquired bleeding and thrombophilia (such as hemophilia patients, coagulopathy, thrombocytopenia, hypersplenism, etc.)
- Long-term unhealed wound or fracture.
- Major surgery or severe traumatic injury, fracture or ulceration within 4 weeks of enrollment.
- Factors that have a significant impact on oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction.
- Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months prior to enrollment.
- Urine routine indicates urinary protein ≥ ++, or confirmed 24-hour urine protein ≥ 1.0 g.
- Has a history of psychiatric drugs abuse and can't quit or have a mental disorder.
- Participated in other clinical trials of anti-tumor drugs within 4 weeks prior to enrollment.
- Previous or concurrent with other unhealed malignant tumors, except for cured skin basal cell carcinoma, cervical carcinoma in situ, and superficial bladder cancer.
- Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures.
- The investigator judges other conditions that may affect the conduct of the clinical study and the determination of the results of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apatinib,Pemetrexe
Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd
|
Apatinib 500 mg Po qd
Pemetrexe 500 mg/m2 d1×q3w
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival(PFS)
Time Frame: Up to three years
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to three years
|
Up to three years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Up to three years
|
From date of randomization until the date of death from any cause, assessed up to three years
|
Up to three years
|
Disease control rate
Time Frame: Up to three years
|
Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1(RECIST1.1).DCR includes CR, PR, SD.Complete remission (CR): All target lesions disappeared completely except for nodular disease.
All target nodules must be reduced to normal size (short axis <10 mm).
All target lesions must be evaluated.Partial Remission (PR): The sum of the diameters of all measurable target lesions is ≥30% below baseline.
The sum of the target nodules uses a short diameter, and the sum of all other target lesions uses the longest diameter.
All target lesions must be evaluated.Stable disease (SD): The extent of target lesion reduction did not reach PR, and the degree of increase did not reach PD level.
Between the two, the minimum value of the sum of diameters could be used as a reference.
|
Up to three years
|
Objective response rate
Time Frame: Up to three years
|
ORR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments.ORR includes CR,PR.Stable disease (SD): The extent of target lesion reduction did not reach PR, and the degree of increase did not reach PD level.
Between the two, the minimum value of the sum of diameters could be used as a reference.Stable disease (SD): The extent of target lesion reduction did not reach PR, and the degree of increase did not reach PD level.
Between the two, the minimum value of the sum of diameters could be used as a reference.
|
Up to three years
|
Health related quality of life
Time Frame: Up to three years
|
HRQoL will be evaluated based on the patient's response to the FACT-L questionnaire.
The FACT-L questionnaire was validated to assess the quality of life of patients with lung cancer.
The 36-item questionnaire consists of four aspects: physical status, functional status, emotional status, and social/family status.
The answer consists of "none" to "very" different levels of choice.
The FACT-L questionnaire has a total score of 0 to 136 points.
Higher scores indicate poor patient quality of life.
|
Up to three years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Folic Acid Antagonists
- Pemetrexed
- Apatinib
Other Study ID Numbers
- XQonc-011
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Non-squamous Non-small-cell Lung Cancer
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
Eli Lilly and CompanyWithdrawnMetastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung CancerItaly, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
-
National Cancer Institute (NCI)RecruitingStage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell CarcinomaUnited States
-
AIO-Studien-gGmbHAstraZenecaTerminatedNSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR MutationGermany
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingLung Cancer | Non Small Cell Lung Cancer | Metastatic Lung Cancer | Advanced Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | Squamous Cell Lung CancerUnited States
-
Western Regional Medical CenterTerminatedNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung CancerUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownAdvanced Non-squamous Cell Non-small Cell Lung CancerChina
-
Qianfoshan HospitalRecruitingAdvanced Non-squamous Non-Small-Cell Lung CancerChina
Clinical Trials on Apatinib
-
Elevar TherapeuticsCompletedAdenoid Cystic CarcinomaUnited States, Korea, Republic of
-
Shanghai Jiao Tong University Affiliated Sixth...UnknownSoft Tissue Sarcoma
-
Tianjin Medical University Cancer Institute and...Unknown
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 InhibitorChina
-
Peking University Cancer Hospital & InstituteRecruiting
-
Huazhong University of Science and TechnologyUnknown
-
Wuhan Union Hospital, ChinaWithdrawnColorectal Cancer | Chemotherapy | Angiogenesis
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.Unknown
-
Ruijin HospitalActive, not recruitingGastric and Gastroesophageal Junction (GEJ) AdenocarcinomaChina